Novartis (NOVN) Given a CHF 102 Price Target at Goldman Sachs Group

Goldman Sachs Group set a CHF 102 price objective on Novartis (VTX:NOVN) in a report released on Tuesday, Borsen Zeitung reports. The firm currently has a buy rating on the stock.

A number of other equities analysts also recently issued reports on the company. UBS Group set a CHF 82 price objective on Novartis and gave the stock a neutral rating in a report on Wednesday, April 24th. HSBC set a CHF 83 price objective on Novartis and gave the stock a neutral rating in a report on Thursday, April 25th. Deutsche Bank set a CHF 85 price objective on Novartis and gave the stock a neutral rating in a report on Friday, April 5th. Barclays set a CHF 75 price objective on Novartis and gave the stock a sell rating in a report on Friday, February 1st. Finally, JPMorgan Chase & Co. set a CHF 85 price objective on Novartis and gave the stock a sell rating in a report on Friday, February 1st. Three analysts have rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the stock. The company presently has an average rating of Hold and a consensus target price of CHF 89.06.

Novartis has a twelve month low of CHF 72.45 and a twelve month high of CHF 88.30.

Novartis Company Profile

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Featured Article: How does the Federal Reserve determine interest rates?

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.